Published: Jun, 2018
The global biological drugs market is anticipated in a report by Transparency Market Research (TMR) to gain immensely from billions of dollars of investment from pharmaceutical companies attracted to lucrative business opportunities available in biologics. In order to take large strides in their market and the prime mover advantage, pharmas such as Bristol-Myers Squibb and Eli Lilly and Company have already made massive biologics investments. Biopharma-related partnerships are said to involve colossal amounts of money, where the acquisition of Baxalta by Shire at a US$32.00 bn is considered to have topped such types of deals singlehandedly. With a view to add a blockbuster drug to its cancer pipeline, Pfizer acquired Medivation for a US$14.00 bn.
TMR projects the global biological drugs market to be valued at a mammoth US$287.14 bn by the completion of 2020. By therapeutic protein, the market could witness the rise of Enbrel since it had secured massive demand in the recent past. On the basis of region, North America is foreseen to lead the market in the near term.
Increasing Incidence of Cancer and Diabetes Fuels Demand for Biological Drugs
The world biological drugs market is predicted to gain momentum with rising prevalence of chronic diseases such as cancer and diabetes across the globe. Demand for biological drugs could swell with the expansion of geriatric population at the global level. Currently growing inclination toward adoption of personalized medicines and strong research and development efforts taken to introduce new and powerful biological drugs are foretold to set the tone for a significant rise in demand.
In China and the U.S., the concept of cost-effective production is largely upheld by the governments with their supportive initiatives. The momentum is expected to increasingly shift in the favor of in vitro production due to benefits such as time and cost-efficiency.
Stringent Regulations and Manufacturing Procedures Upset Market Growth
The international biological drugs market is envisaged to grow at a handsome rate in the next few years. However, it could face challenges in the form of various product parameters, strict regulatory pathways and manufacturing processes, and longer product approvals, although biological drugs have historically shown better approval rates than conventional ones. Additionally, small players could find it difficult to enter the market because of the requirement of high capital expenditure.
Nevertheless, companies could make their presence known in the international biological drugs market by developing new vaccines for severe infections such as those caused by C. difficile and Meningococcal B. The market could also offer rewarding prospects on the back of vaccination programs sponsored by governments. This scenario could be particularly taken notice of in Australia and India. Enormous venture capital investment in biotechnologies is envisioned to create profit-making opportunities in the market.
The information presented in this review is based on a TMR report, titled “Biological Drugs Market (Therapeutic Protein - Levemir, Neulasta, Eylea, Rebif, NovoLog, Enbrel, Avonex, Neupogen, Humalog, Victoza, Lantus, Epogen, Aranesp, and Betaseron; Monoclonal Antibody - Avastin, Rituxan, Lucentis, Humira, Herceptin, and Remicade; Vaccine - Gardasil, Prenvar 13, Fluzone, Cervarix, and Varivax) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020.”
The global biological drugs market has been segmented as presented below:
Global Biological Drugs Market: Therapeutic Protein
Global Biological Drugs Market: Monoclonal Antibody
Global Biological Drugs Market: Vaccine
- Prenvar 13
Global Biological Drugs Market: Region
- North America
- Rest of the World
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453